BC
NVO

Bridgefront Capital’s Novo Nordisk NVO Stock Holding History

Bridgefront Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,278
Closed -$237K – 701
2025
Q3 		$237K Buy
+4,278
New +$250K 0.07% 470
2025
Q2 		– Sell
-10,216
Closed -$709K – 774
2025
Q1 		$709K Buy
10,216
+6,253
+158% +$516K 0.2% 164
2024
Q4 		$341K Buy
+3,963
New +$429K 0.11% 323
2023
Q3 		– Sell
-4,154
Closed -$336K – 546
2023
Q2 		$336K Buy
+4,154
New +$339K 0.18% 217
2021
Q2 		– Sell
-24,400
Closed -$823K – 810
2021
Q1 		$823K Buy
24,400
+17,592
+258% +$627K 0.26% 92
2020
Q4 		$238K Buy
+6,808
New +$235K 0.08% 455

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bridgefront Capital's NVO Position: Q4 2025 in Review

Bridgefront Capital sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 4,278 shares — an estimated $237K sold.

Bridgefront Capital first reported a position in NVO in Q4 2020 and held it in 6 quarters. The position peaked at $823K in Q1 2021. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Bridgefront Capital reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Bridgefront Capital sold 4,278 Novo Nordisk shares in Q4 2025, an estimated $237K.
  • Bridgefront Capital first reported a position in Novo Nordisk in Q4 2020 and held it in 6 quarters.
  • Bridgefront Capital's Novo Nordisk position peaked at $823K in Q1 2021.
  • 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.